Clearside Biomedical (NASDAQ:CLSD) Given New $5.00 Price Target at HC Wainwright

Clearside Biomedical (NASDAQ:CLSDFree Report) had its price target reduced by HC Wainwright from $6.00 to $5.00 in a report issued on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Clearside Biomedical’s Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($0.56) EPS.

Several other analysts have also recently commented on CLSD. Wedbush reaffirmed an outperform rating and issued a $4.00 target price (down from $5.00) on shares of Clearside Biomedical in a research note on Wednesday, March 13th. JMP Securities reissued a market outperform rating and set a $5.00 price objective on shares of Clearside Biomedical in a research note on Wednesday, March 13th. Needham & Company LLC reissued a buy rating and set a $4.00 price objective on shares of Clearside Biomedical in a research note on Thursday, April 11th. Finally, StockNews.com cut shares of Clearside Biomedical from a hold rating to a sell rating in a research note on Friday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $4.50.

Read Our Latest Stock Report on Clearside Biomedical

Clearside Biomedical Price Performance

Shares of Clearside Biomedical stock opened at $1.23 on Monday. Clearside Biomedical has a 1 year low of $0.65 and a 1 year high of $2.12. The company has a market capitalization of $91.91 million, a P/E ratio of -2.24 and a beta of 2.35. The business has a 50 day moving average price of $1.44 and a 200 day moving average price of $1.27.

Clearside Biomedical (NASDAQ:CLSDGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.98 million. During the same period in the prior year, the company earned ($0.15) EPS. As a group, research analysts expect that Clearside Biomedical will post -0.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Clearside Biomedical news, insider Ngai Hang Victor Chong purchased 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was purchased at an average cost of $1.60 per share, with a total value of $48,000.00. Following the transaction, the insider now owns 30,000 shares in the company, valued at $48,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.80% of the stock is owned by corporate insiders.

Institutional Trading of Clearside Biomedical

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Clearside Biomedical by 14.5% in the 1st quarter. Vanguard Group Inc. now owns 2,490,796 shares of the company’s stock worth $3,811,000 after buying an additional 314,480 shares in the last quarter. SG Americas Securities LLC acquired a new position in Clearside Biomedical in the 1st quarter worth $49,000. International Assets Investment Management LLC acquired a new position in Clearside Biomedical in the 1st quarter worth $57,000. Finally, Rosalind Advisors Inc. acquired a new position in Clearside Biomedical in the 1st quarter worth $3,967,000. 18.75% of the stock is owned by hedge funds and other institutional investors.

Clearside Biomedical Company Profile

(Get Free Report)

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.

See Also

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.